Science, medicine, and the future: Pathogenesis of sepsis: New concepts and implications for future treatment

British Medical Journal

Volumn 326, Issue 7383, 2003, Pages 262-266

  Bochud, Pierre Yves ^a   Calandra, Thierry ^b  

^a INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; HIGH MOBILITY GROUP B1 PROTEIN; MACROPHAGE MIGRATION INHIBITION FACTOR; TOLL LIKE RECEPTOR; CELL SURFACE RECEPTOR; DROSOPHILA PROTEIN; HIGH MOBILITY GROUP A1A PROTEIN; MEMBRANE PROTEIN;

BACTERIAL CELL WALL; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNE RESPONSE; PATHOGENESIS; PATTERN RECOGNITION; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTIC SHOCK; BACTERIAL INFECTION; GENETIC PREDISPOSITION; GRAM NEGATIVE INFECTION; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; DROSOPHILA PROTEINS; GENETIC PREDISPOSITION TO DISEASE; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HMGA1A PROTEIN; HUMANS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MEMBRANE GLYCOPROTEINS; RECEPTORS, CELL SURFACE; SEPSIS; TOLL-LIKE RECEPTORS;

EID: 0037309925     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.326.7383.262     Document Type: Review

References (30)

1. Centers for Disease Control. Increase in national hospital discharge survey races for septicemia - United States, 1979-1987. JAMA 1990;263:937-8.
2. Angus DC, Linde-Zwirble WT. Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10.
3. Bochud PY, Glauser MP, Calandra T. Antibiotics in sepsis. Intensive Care Med 2001;27(suppl 1):S33-48.
4. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002;20:197-216.
5. Calandra T, Bochud PY, Heumann D. Cytokines in septic shock. In: Remington JS, Swartz MN, eds. Current clinical topics in infectious diseases. Oxford: Blackwell Publishing, 2002:1-23.
6. Alexander C, Rietschel ET. Bacterial lipopolysaccharides and innate immunity. J Endotoxin Res 2001;7:167-202.
7. Ulevitch RJ, Tobias PS. Recognition of gram-negative bacteria and endotoxin by the innate immune system. Curr Opin Immunol 1999;11:19-22.
8. Hoffmann JA, Reichhart JM. Drosophila innate immunity: an evolutionary perspective. Nat Immunol 2002;3:121-6.
9. Poltorak A, He X, Smirnova I, Liu MY, Huffel CV, Du X, et al. Defective LPS signalling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998;282:2085-8.
10. Nagai Y, Akashi S, Nagafuku M, Ogata M, Iwakura Y, Akira S, et al. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol 2002;3:667-72.
11. Calandra T. Pathogenesis of septic shock: implications for prevention and treatment. J Chemother 2001;13:173-80.
12. Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, et al. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 1999;11:443-51.
13. Cohen J, Abraham E. Microbiologic findings and correlations with serum tumor necrosis factor-alpha in patients with severe sepsis and septic shock. J Infect Dis 1999;180:116-21.
14. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001;410:1099-103.
15. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000;408:740-5.
16. Ozinsky A, Underhill DM, Fontenot JD, Hajjar AM, Smith KD, Wilson CB, et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci USA 2000;97:13766-71.
17. Kaisho T, Akira S. Toll-like receptors as adjuvant receptors. Biochim Biophys Acta 2002;1589:1-13.
18. Vincent JL, Sun Q, Dubois MJ. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 2002;34:1084-93.
19. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
20. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862-71.
21. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77.
22. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345:1359-67.
23. Cross AS, Sadoff JC, Kelly N, Bernton E, Gemski P. Pretreatnent with recombinant murine tumor necrosis factor alpha/cachectin and murine interleukin 1 alpha protects mice from lethal bacterial infection. J Exp Med 1989;169:2021-7.
24. Froidevaux C, Roger T, Martin C, Glauser MP, Calandra T. Macrophage migration inhibitory factor and innate immune responses to bacterial infections. Crit Care Med 2001:29:S13-5.
25. Roger T, David J, Glauser MP, Calandra T. MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature 2001;414:920-4.
26. Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, Hultner L, et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000;6:164-70.
27. Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelter W, et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 1993;365:756-9.
28. Bozza M, Satoskar AR, Lin G, Lu B, Humbles AA, Gerard C, et al. Targeted disruption of migration inhibitory factor gone reveals its critical role in sepsis. J Exp Med 1999;189:341-6.
29. Wang H, Yang H, Czura CJ, Sama AE, Tracey KJ. HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med 2001;164:1768-73.
30. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248-51.